Charles Schwab’s Verve Therapeutics VERV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-592,436
| Closed | -$6.65M | – | 3544 |
|
|
2025
Q2 | $6.65M | Buy |
592,436
+24,252
| +4% | +$138K | ﹤0.01% | 2206 |
|
|
2025
Q1 | $2.6M | Sell |
568,184
-2,534
| -0.4% | -$17K | ﹤0.01% | 2530 |
|
|
2024
Q4 | $3.22M | Sell |
570,718
-1,455
| -0.3% | -$8.21K | ﹤0.01% | 2528 |
|
|
2024
Q3 | $2.77M | Buy |
572,173
+126,110
| +28% | +$732K | ﹤0.01% | 2605 |
|
|
2024
Q2 | $2.18M | Sell |
446,063
-40,944
| -8% | -$257K | ﹤0.01% | 2683 |
|
|
2024
Q1 | $6.47M | Buy |
487,007
+117,337
| +32% | +$1.56M | ﹤0.01% | 2191 |
|
|
2023
Q4 | $5.15M | Buy |
369,670
+6,626
| +2% | +$82.1K | ﹤0.01% | 2301 |
|
|
2023
Q3 | $4.81M | Buy |
363,044
+27,605
| +8% | +$445K | ﹤0.01% | 2279 |
|
|
2023
Q2 | $6.29M | Buy |
335,439
+13,139
| +4% | +$219K | ﹤0.01% | 2136 |
|
|
2023
Q1 | $4.65M | Buy |
322,300
+1,723
| +0.5% | +$33.7K | ﹤0.01% | 2241 |
|
|
2022
Q4 | $6.2M | Buy |
320,577
+13,724
| +4% | +$364K | ﹤0.01% | 2107 |
|
|
2022
Q3 | $10.5M | Buy |
306,853
+161,963
| +112% | +$5.17M | ﹤0.01% | 1803 |
|
|
2022
Q2 | $2.21M | Sell |
144,890
-8,660
| -6% | -$134K | ﹤0.01% | 2542 |
|
|
2022
Q1 | $3.5M | Buy |
153,550
+48,824
| +47% | +$1.4M | ﹤0.01% | 2452 |
|
|
2021
Q4 | $3.86M | Buy |
104,726
+1,916
| +2% | +$80.5K | ﹤0.01% | 2476 |
|
|
2021
Q3 | $4.83M | Buy |
+102,810
| New | +$6.05M | ﹤0.01% | 2390 |
|
Other funds holding VERV
GCM
BIG
IA
